48.87 0.00 (0.00%)
After hours: 4:05PM EDT
|Bid||47.65 x 1200|
|Ask||49.75 x 1200|
|Day's Range||48.57 - 49.97|
|52 Week Range||26.02 - 56.67|
|Beta (3Y Monthly)||2.40|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 1) Alcon AG (NYSE: ALC ) (announced presentation of new ...
NovoCure (NVCR) delivered earnings and revenue surprises of 0.00% and -0.44%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Saint Helier, Jersey-based company said it had a loss of 13 cents per share. The results met Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The most you can lose on any stock (assuming you don't use leverage) is 100% of your money...
On CNBC's "Mad Money Lightning Round," Jim Cramer said Entergy Corporation (NYSE: ETR ) is a big winner. He likes the company very much. Novocure Ltd (NASDAQ: NVCR ) is a good company and one ...
The market has been volatile in the fourth quarter as the Federal Reserve continued its rate hikes to normalize the interest rates. Small cap stocks have been hit hard as a result, as the Russell 2000 ETF (IWM) has underperformed the larger S&P 500 ETF (SPY) by nearly 7 percentage points. SEC filings and hedge […]
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors are always looking for growth in small-cap stocks like NovoCure Limited (NASDAQ:NVCR), with a market cap of US$4.4b. However, an important fact which most ignore is: how financially healthy is the business...
Despite last month's pullback, shares of this medical device company that's aiming to revolutionize cancer treatment are up 126% over the last year.
Novocure Ltd. said Thursday Chief Science Officer Eilon Kirson will retire after about 7 years in the role, and 17 years with the company. The cancer treatment company said Kirson's retirement provides the opportunity to separate medical and scientific responsibilities. Uri Weinberg, vice president of clinical development, will assume responsibilities for preclinical and clinical development and regulatory affairs effective immediately, and Ely Benaim will join the company as chief medical officer effective April 1, assuming responsibilities for clinical operations, medical affairs and safety. The stock, which is still inactive in premarket trade has soared 67.8% over the past three months, while the iShares Nasdaq Biotechnology ETF has rallied 24.6% and the S&P 500 has climbed 16.9%.
Analyzing NovoCure Limited's (NASDAQ:NVCR) track record of past performance is a valuable exercise for investors. It enables us to reflect on whether or not the company has met expectations, whichRead More...
CEO of Novocure Ltd (NASDAQ:NVCR) Asaf Danziger sold 100,000 shares of NVCR on 03/01/2019 at an average price of $55.57 a share.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
CEO of Novocure Ltd (NASDAQ:NVCR) Asaf Danziger sold 200,000 shares of NVCR on 01/17/2019 at an average price of $45.16 a share.
Tamarack Capital Management is a hedge fund that was founded by Mr. Justin John Ferayorni, its current Chief Investment Officer and Portfolio Manager. Before deciding to start his own firm, Mr. Ferayorni built up serious experience in investing, working as a Healthcare Analyst and Portfolio Manager, and later own as a Director of Research at […]
Pharmaceutical companies in the Triangle were far from exempt from a worldwide dive in stock prices, with some companies sliding more than 50 percent.